MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2023 International Congress

    Common oscillatory patterns between Parkinson’s disease and heroin dependent patients: a resting-state EEG study

    D. Benis, V. Fleury, P. Krack (Geneva, Switzerland)

    Objective: We aimed to compare resting-state EEG oscillations between Parkinson’s disease (PD) patients during their ON and OFF Dopamine Replacement Therapy (DRT) states, heroin-dependent (HD)…
  • 2023 International Congress

    Continuous algorithmic insights into PD motor symptoms and individual treatment response

    M. Sander, FMJ. Pfister, G. Höglinger, J. Levin, A. Ceballos-Baumann, UM. Fietzek (Munich, Germany)

    Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…
  • 2023 International Congress

    Early versus late levodopa administration in Parkinson’s disease: Comparative study

    A. Akid, I. Kacem, A. Guedi, Y. Abida, S. Mrabet, A. Souissi, A. Gharbi, A. Nasri, R. Gouider (Tunis, Tunisia)

    Objective: To evaluate levodopa-sparing strategy in terms of motor decline and complications. Background: Levodopa remains the gold standard for treatment of Parkinson’s disease(PD), as it…
  • 2023 International Congress

    The Short Duration Response and Long Duration Response to L-Dopa are Needed to Restore Vigor-Motivation Coupling in Parkinson Disease

    J. Brissenden, T. Scerbak, R. Albin, T. Lee (Ann Arbor, USA)

    Objective: To assess the relationship between the Short Duration Response (SDR) and Long Duration Response (LDR) to L-Dopa therapy in Parkinson disease (PD) and restoration…
  • 2023 International Congress

    Pharmacokinetics, Safety and Tolerability of Foslevodopa/Foscarbidopa Following Continuous Subcutaneous Infusion to Arm, Thigh and Flank compared to Abdomen in Parkinson’s Disease Patients

    Y. Han, H. Kalluri, A. Jeong, C. Locke, M. Facheris, S. Gupta, M. Rosebraugh (North Chicago, USA)

    Objective: To characterize safety/tolerability and pharmacokinetics (PK) of levodopa (LD) and carbidopa (CD) after delivery of foslevodopa/foscarbidopa in Parkinson’s disease (PD) patients at 4 different…
  • 2023 International Congress

    Testing the applicability of the dysarthria analyzer to detect levodopa effects on speech in a German cohort of people with Parkinson’s disease

    T. Thies, J. Schreen, H. Jergas, M. Barbe (Cologne, Germany)

    Objective: To test the applicability of “the dysarthria analyzer” in a levodopa challenge test to determine short term effects of levodopa on acoustic speech parameters.…
  • 2023 International Congress

    Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for patients with Parkinson’s disease and motor fluctuations: Results from the Phase 3 randomized, active-controlled BouNDless study

    O. Rascol, A. Albanese, A. Ellenbogen, J. Ferreira, N. Giladi, T. Gurevich, S. Hassin-Baer, J. Hernandez-Vara, S. Isaacson, K. Kieburtz, P. Lewitt, L. Lopez-Manzanares, CW. Olanow, R. Pahwa, W. Poewe, H. Sarva, F. Stocchi, T. Yardeni, L. Adar, L. Salin, N. Lopes, N. Sasson, R. Case, A. Espay (Toulouse, France)

    Objective: Determine the efficacy, safety, and tolerability of ND0612 versus oral immediate-release levodopa/carbidopa (IR-LD/CD) in people with Parkinson’s disease (PwP) experiencing motor fluctuations. Background: ND0612…
  • 2023 International Congress

    Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion

    Y. Ben Mordechai, S. Israeli-Korn, O. Cohen, S. Hassin-Baer (Tel Hashomer, Israel)

    Objective: To compare levodopa/carbidopa intestinal gel (LCIG) with equally distributed dietary protein (Diet_EDP) versus restricted to twice daily (Diet_RP) and Mediterranean diet (Diet_M). Background: Levodopa…
  • 2023 International Congress

    Marked reduction of energy supply due to levodopa treatment in patients with Parkinson’s disease and healthy controls

    J. Prasuhn, T. Schiefen, T. Grüber, J. Hekel, J. Uter, J. Steinhardt, B. Wilms, N. Brüggemann (Lübeck, Germany)

    Objective: To investigate the influence of a standardized, placebo-controlled administration of levodopa on cerebral bioenergetics in patients with Parkinson’s disease (PwPD) and healthy controls (HCs).…
  • 2023 International Congress

    Stability and predictability of motor symptom control in patients with advanced Parkinson’s disease (aPD) receiving continuous subcutaneous foslevodopa/foscarbidopa (LDP/CDP)

    R. Pahwa, I. Malaty, M. Soileau, V. Fung, D. Santos Garcia, C. Carroll, T. Henriksen, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, M. Shah, P. Kukreja, J. Zamudio, K. Chaudhuri (Kansas City, USA)

    Objective: To evaluate temporal changes in motor states (OFF and ON without troublesome dyskinesia [TD; good ON]) throughout the waking day in patients with aPD…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley